Inflammatory Bowel Disease (IBD) is a complicated disease that is triggered and exacerbated by a slew of genetic factors and environmental stimuli that wreak havoc on the immune-microbiome axis. The two principal forms of IBD are ulcerative colitis (UC) and Crohn's disease (CD). These two diseases represent chronic gastrointestinal tract inflammation, which varies in symptoms and inflammatory burden between patients. Even though specific immunosuppressive drugs are used more frequently in traditional medical therapy for inflammatory bowel disease, compared to dietary interventions, response rates are still low. As a result, there is a pressing need to investigate dietary components that could help patients not only enhance their response to conventional therapy but also serve as a primary or maintenance treatment. Methodology: A non-randomized multicenter open-label controlled study was conducted where a total of 113 patients having IBD were allocated into either the modified Specific Carbohydrate Diet (mSCD) group or the control group. Patients in the control group (n=55) were allowed to eat as they please whereas patients in the treatment group (n=58) followed the mSCD for 8 weeks. After enrolment patients are evaluated at the beginning of the study and after 8 weeks. Simple Clinical Colitis Activity Index (SCCAI), Harvey Bradshaw Index (HBI), Faecal Calprotectin (FC), and C-reactive protein (CRP) evaluations were assessed. Data collection took place from the 1st of July 2021 to the 8th of May 2022. Results: Based on the SCCAI score, 3 (9.4%) of the patients with UC achieved remission in the control group. While in the mSCD group, 11 (32.4%) achieved remission in 8 weeks. According to HBI, 12 (50%) of CD patients in the case group achieved remission. In contrast, one patient only achieved remission in the control group. Regarding the FC changes among patients with UC, the mean CRP levels in the mSCD group were significantly decreased (P <0.05). In addition, the reduction was significant among those with mild to moderate or severe presentation in the mSCD group. The mean CRP and FC levels for patients with CD decreased significantly in the mSCD group (P<0.05). Conclusion: All patients with UC or CD showed a significant response to the intervention that was assessed by clinical assessment through SCCAI and HBI and laboratory investigations including CRP and FC. The mSCD appeared to be an effective approach to establishing and maintaining remission for patients with UC or CD.